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Purpose: While the long-term incidence of hydroxychloroquine (HCQ) retinopathy is low, there 
remains no definitive clinical screening test to recognize HCQ toxicity before ophthalmoscopic 
fundus changes or visual symptoms. Patients receiving HCQ were evaluated with spectral 
domain optical coherence tomography (SD OCT) to assess the feasibility of identifying HCQ 
retinopathy at an early stage.
Methods: Twenty-five patients referred for the evaluation of hydroxychloroquine toxicity 
underwent a comprehensive ocular examination, Humphrey visual field (HVF) perimetry, time 
domain OCT, and SD OCT. Some patients with screening abnormalities also underwent further 
diagnostic testing at the discretion of the treating providers.
Results: Five patients were found to have SD OCT findings corresponding to HCQ toxicity 
and retinal damage as seen by clinical exam and/or HVF perimetry. Two patients with advanced 
toxicity were found to have significant outer retina disruption in the macula on SD OCT. 
Three patients with early HCQ toxicity and HVF 10-2 perifoveal defects were found to have 
loss of the perifoveal photoreceptor inner segment/outer segment (IS/OS) junction with intact 
outer retina directly under the fovea, creating the “flying saucer” sign. While two of these three 
patients had early ophthalmoscopic fundus changes, one had none.
Conclusion: Outer retinal abnormalities including perifoveal photoreceptor IS/OS junction 
disruption can be identified by SD OCT in early HCQ toxicity, sometimes even before 
ophthalmoscopic fundus changes are apparent. SD OCT may have a potential complementary 
role in screening for HCQ retinopathy due to its quick acquisition and because it is more 
objective than automated perimetry.
Keywords: drug toxicity, hydroxychloroquine, photoreceptors, screening test, spectral domain 
optical coherence tomography
Introduction
The use of hydroxychloroquine (HCQ), an antimalarial drug utilized for a range of rheu-
matologic and dermatologic diseases, is associated with a low incidence of retinopathy 
(0.5%) when used at recommended doses (,6.5 mg/kg per day).1 It has largely replaced 
chloroquine because of decreased ocular toxicity at high dosages,2 but can still lead to 
potentially irreversible visual loss. Although multiple modalities have been proposed for 
the screening, there remains no “gold standard” for the identification of HCQ toxicity 
before the onset of decreased vision or ophthalmoscopic fundus changes.3 In 2002, the 
American Academy of Ophthalmology published preferred practice patterns for HCQ 
retinopathy screening. Recommendations included a comprehensive eye exam and 
Humphrey visual field (HVF) (Humphrey Instruments Inc., San Leandro, CA, USA) Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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10-2 perimetry or Amsler grid testing, with other testing left 
to the discretion of the provider. Follow-up was based on risk 
factors including dosage, duration of use, body habitus, liver 
or renal function, concomitant retinal disease, and age. How-
ever, it was acknowledged that even with screening, severe 
vision loss is still possible.4 At the present time, it is still not 
known whether the crucial factor in developing toxicity is 
daily dose, duration of usage, or cumulative dose.5
Patients may present with a range of complaints; while 
some are asymptomatic, others will have problems with 
central vision or field defects, glare, night blindness, or defi-
ciencies in color vision.6,7 Clinical changes tend to be a late 
finding in HCQ retinopathy and are characterized by bilateral 
pigmentary macular changes, often sparing the foveal center 
and leading to a characteristic “bull’s eye” maculopathy. 
Paracentral scotomas on HVF 10-2 perimetry correlate well 
with retinal damage and may appear before other clinical 
findings are apparent.8 Color vision testing defects and abnor-
malities in fluorescein angiography (FA) and electroretinog-
raphy (ERG) can also be seen.6,9,10 The exact mechanism of 
retinal toxicity is unknown; previous studies have implicated 
damage to outer retinal structures11,12 such as photoreceptors 
and retinal pigment epithelium cells, while others have sus-
pected damage to retinal ganglion cells, the inner plexiform 
layer, or the retinal nerve fiber layer.13–15
Recently, a research prototype of an ultra-high resolution 
optical coherence tomography (OCT) system identified dis-
tinctive abnormalities in the perifoveal photoreceptor inner 
segment/outer segment (IS/OS) junction in symptomatic 
patients with HCQ toxicity and findings on visual fields and 
multifocal ERG.16 Patients with more advanced retinopathy 
were also found to have thinning of the outer nuclear layer. 
Our study was designed to evaluate the utility of commercially 
available spectral domain OCT (SD OCT) systems for their 
ability to detect early retinal changes due to HCQ toxicity.
Methods
Charts from consecutive patients referred for the evaluation of 
HCQ retinopathy were reviewed retrospectively. All patients 
underwent a comprehensive eye examination, HVF 10-2 
perimetry, time domain OCT imaging (Stratus; Carl Zeiss 
Meditec, Inc., Dublin, CA, USA), and SD OCT imaging 
with both the Heidelberg Spectralis HRA + OCT (Spectralis; 
Heidelberg Engineering, Heidelberg, Germany) and Cirrus 
HD-OCT (Cirrus; Carl Zeiss Meditec, Inc., Dublin, CA, USA). 
Based on the results of the above screening examinations and 
per the discretion of the treating physician, some patients also 
had fundus autofluorescence imaging (FAF), color fundus 
photography, FA, and multifocal electroretinogram testing. 
Charts were reviewed for HCQ dose and duration, indication 
for HCQ use, clinical exam findings, and imaging results. 
The Institutional Review Board of The Methodist Hospital 
in Houston, TX, approved the study protocol.
Results
Twenty-five patients (one male, 24 female, mean age of 
55 with range of 28–78) were referred for the evaluation 
of HCQ retinopathy (Table 1). Indications for HCQ usage 
included: 12 for systemic lupus erythematosus, six for rheu-
matoid arthritis, three for lichen planopilaris, two for Sjogren’s 
syndrome, and one each for scleroderma, dermatomyositis, 
and unspecified antinuclear antibody positive disease. For this 
study we included all patients referred to our practice for 
evaluation of HCQ retinopathy; several patients were referred 
for “baseline” examinations, and the longest duration of treat-
ment was 22 years. Most patients were on standard dosages 
of 200 or 400 mg daily, but when bodyweight was taken into 
consideration, seven of the 25 were on dosages higher than 
the recommended 6.5 mg/kg/day. Cumulative dosages of 
HCQ excluding those patients seen for baseline evaluations 
ranged from 146 to 2920 g.
Nine of the 25 patients were found to have funduscopic 
changes suspicious for HCQ toxicity, ranging anywhere from 
mild RPE changes to advanced bull’s eye maculopathy, while 
16 patients presented without any clinical signs of HCQ 
toxicity. Two patients who presented with macular pucker and 
one who presented with drusen alone were not considered to 
have retinal changes consistent with possible HCQ retinopathy. 
Out of the nine patients with funduscopic abnormalities, four 
had no defects on either HVF 10-2 perimetry or SD OCT 
testing. The remaining five patients all had visual field defects 
on HVF 10-2 perimetry, and four of these had abnormalities 
on SD OCT. Of the 16 patients with normal funduscopic 
exams, eight patients had HVF 10-2 abnormalities while only 
one had changes on SD OCT.
In patients with early HCQ retinopathy, SD OCT imaging 
showed loss of the perifoveal photoreceptor IS/OS junction, 
perifoveal thinning of the outer nuclear layer, and an appar-
ent posterior displacement of the inner retinal structures 
toward the retinal pigment epithelium. This displacement led 
to variable loss of the normal foveal depression, and when 
combined with preservation of an intact photoreceptor IS/OS 
junction within the foveal region, created a “flying saucer” 
sign (Figure 1). We have chosen the term “flying saucer”, a 
well recognized shape in the popular media, to describe the 
apparent ovoid appearance of the central fovea created by Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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preservation of the outer retinal structures in the central fovea 
surrounded by perifoveal loss of the photoreceptor IS/OS 
junction and perifoveal outer retinal thinning.
Five of the 25 patients had abnormal SD OCT findings 
that correlated with exam and/or HVF perimetry findings 
suspicious for HCQ retinopathy. Duration of treatment with 
HCQ in these patients ranged from 2 to 20 years, HCQ daily 
dose adjusted for bodyweight ranged from 2.9 to 8.4 mg/kg, 
and cumulative dose ranged from 292 to 2920 g. Three of the 
five patients were aware of vision changes, and while four 
had abnormalities on funduscopic exam, one of the patients 
had a normal ophthalmologic fundus exam. All five patients 
did have abnormalities on HVF 10-2 perimetry, ranging 
from paracentral to dense scotomas. In the five patients with 
SD OCT abnormalities, 3 had signs of early HCQ retinopathy 
while 2 had advanced changes. The “flying saucer” sign was 
present in all three of the five patients who presented with 
early HCQ retinopathy.
Two patients presented with advanced HCQ retinopathy and 
moderate to severe vision loss. Funduscopic findings ranged 
from pronounced bull’s eye maculopathy to severe macular 
atrophy. SD OCT findings ranged from disruption of outer reti-
nal integrity with preservation of foveal IS/OS photoreceptors 
to complete structural disorganization of the outer retina.
Normal SD OCT images with preservation of perifoveal 
outer retinal structures were seen in 20 of the 25 patients. 
Duration of treatment with HCQ in these patients ranged 
from less than one year to 22 years, daily doses from 3.0 
to 7.2 mg/kg, and cumulative doses from 146 to 2628 g. 
Of these patients with no SD OCT abnormalities, three 
complained of vision changes and eight had abnormalities 
on HVF 10-2 perimetry.
Discussion
Although it is better tolerated at high dosages than chloro-
quine and infrequently causes retinopathy, HCQ can still 
cause severe irreversible vision loss. HCQ screening for 
identification of early toxicity is critical to allow for cessa-
tion of the drug and potential prevention of vision loss.17 The 
American Academy of Ophthalmology preferred practice 
ILM
IPL
OPL ELM
IS/OS RPE
Figure 1 Top: Normal Spectralis spectral domain optical coherence tomography (SD OCT) image with intact photoreceptor inner segment/outer segment junction (IS/
OS). Bottom: Spectralis SD OCT from the left eye of patient 10 showing the “flying saucer” sign of hydroxychloroquine retinopathy, an ovoid appearance of the central 
fovea created by preservation of central foveal outer retinal structures (seen between the black arrows) surrounded by perifoveal loss of the photoreceptor IS/OS junction, 
and perifoveal outer retinal thinning. 
Abbreviations: iLM, internal limiting membrane; IPL, inner plexiform layer; OPL, outer plexiform layer; ELM, external limiting membrane; RPE, retinal pigment epithelium.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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patterns recommend screening initially for HCQ toxicity with 
a complete ophthalmic exam and either HVF 10-2 perimetry 
or Amsler grid testing, with other testing optional and at 
the discretion of the provider.4,18 While HVF perimetry and 
Amsler grid testing may show abnormalities even before the 
onset of funduscopic changes,8 they are still limited in that 
they only detect toxicity after significant retinopathy has 
occurred. Furthermore, Amsler grid testing is very subjective, 
and automated visual field perimetry has a steep learning 
curve and can be inconclusive. Clinical exam findings can 
be subtle and tend to be a late finding.
Multiple other modalities have been suggested for 
HCQ toxicity screening. Color testing may help detect 
early maculopathy,4 and FA may help in patients who have 
difficulty with visual field testing.17 Fundus autofluorescence 
may detect early retinal pigment epithelium alterations,19 
and preferential hyperacuity perimetry testing may pick 
up defects in early hydroxychloroquine toxicity.20 Several 
other reports suggest that serial multifocal ERGs may detect 
decreased retinal function even earlier than other modalities 
in patients with otherwise normal clinical examinations.21–24 
To date, however, many of these tests are not widely and 
readily available, and there still remains a lack of consensus 
on which diagnostic test is the most useful.
Rodriguez-Padilla et al16 first described some of the 
findings in HCQ toxicity on a research prototype ultra-high 
resolution OCT machine, and other recent case reports have 
reported HCQ retinopathy findings on SD OCT machines.25,26 
In our study, SD OCT abnormalities due to HCQ toxicity were 
identified in five patients when using both SD OCT systems. 
As expected, two patients with advanced HCQ retinopathy 
had SD OCT findings that demonstrated loss of outer retinal 
integrity and structural disorganization that correlated with 
advanced bull’s eye maculopathy and/or macular atrophy seen 
on clinical, angiographic, and with visual field testing. Three 
other patients with earlier stages of HCQ toxicity identified 
by SD OCT all presented with paracentral scotomas seen on 
HVF 10-2 testing usually associated with HCQ retinopathy. 
All three demonstrated characteristic perifoveal outer retinal 
abnormalities seen on SD OCT that we have termed the 
“flying saucer” sign; these findings include preservation of 
the outer retinal structures in the central fovea, perifoveal 
loss of the photoreceptor IS/OS junction and outer retinal 
thinning, posterior or “sinkhole” displacement of the inner 
retinal structures toward the retinal pigment epithelium,25 and 
variable loss of the normal foveal depression.
While the “flying saucer” sign we have described is not 
pathognomonic nor even necessary for the diagnosis of HCQ 
retinopathy, it may be helpful in questionable or inconclusive 
cases when reviewed in the context of clinical findings as well 
as other diagnostic testing. This “flying saucer” may not even 
represent the earliest stage of HCQ toxicity visible on SD OCT, 
as Stepien et al described a “preclinical” stage of HCQ toxicity 
where the photoreceptor IS/OS junction appears “moth-eaten” 
due to preferential loss of cone photoreceptors.25 Even though 
the “flying saucer” sign was poorly visualized using time 
domain OCT that was also performed in all of the patients, 
this perifoveal loss of the photoreceptor IS/OS junction and 
AB
D C
Figure 2 Spectral domain optical coherence tomography (SD OCT) images taken with different commercially available SD OCT machines demonstrate the “flying saucer” 
sign is consistent in different individuals with hydroxychloroquine retinopathy. A) Heidelberg Spectralis SD OCT in patient 9, OD. B) Zeiss Cirrus SD OCT in patient 9, OD. 
C) Heidelberg Spectralis SD OCT in patient 4, OS. D) Zeiss Cirrus SD OCT in patient 4, OS.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Figure  3  Spectral  domain  optical  coherence  tomography  (SD  OCT),  red-free 
photo, fundus autofluorescence, and early and late fluorescein angiogram in patient 
10,  who  had  no  symptoms,  normal  clinical  exam  and  fundus  autofluorescence 
imaging, Humphrey visual field 10-2 with paracentral scotomas, and “flying saucer” 
sign seen on sD OCT.
outer retinal structures was easily visualized and appeared 
consistently in scans across both the Heidelberg Spectralis 
SD-OCT and the Zeiss Cirrus SD-OCT, both commercially 
available OCTs found in many retinal offices (Figure 2).
Patient 4 presented with subtle bull’s eye retinopathy seen 
on both clinical fundus exam and angiographic testing and HVF 
with paracentral scotomas OU; although she had a prior history 
of intermittent HCQ use for a total duration of only 2 years 
over a period of 4 years, she had an adjusted HCQ daily dose 
of 8.4 mg/kg and a “flying saucer” on SD OCT helped confirm 
HCQ retinopathy (Figure 2B). A national database of over 4000 
HCQ patients has found only a few per 1000 with probable 
toxicity in the first 5–7 years of usage (personal communication, 
Marmor), although another review has noted HCQ retinopathy 
in a patient treated for as little as 1.9 months.6 Her symptoms 
appeared to progress even after the cessation of HCQ in 2007, 
which has been previously reported in chloroquine toxicity,27 
although her clinical and SD OCT findings have been stable 
since we first saw her over one year ago in 2009.
In one of the patients with early HCQ retinopathy, the SD 
OCT imaging was particularly helpful in making a timely 
diagnosis of toxicity. Patient 10 (Figure 3) was found to 
have a completely normal fundus exam, autofluorescence, 
and fluorescein angiography. Her time domain OCT was 
unremarkable, but SD OCT demonstrated the “flying 
saucer” sign and thinning of the outer nuclear layer in both 
eyes. HVF 10-2 showed classic paracentral scotomas that 
had progressed significantly from the nonspecific changes 
that were seen in the previous year’s exam; no SD OCT had 
been performed at that time. Although no other clinical or 
ancillary testing was able to detect toxicity in this patient, 
SD OCT findings helped confirm HVF findings. These SD 
OCT findings were maintained 12 months after cessation of 
HCQ with persistence of the “flying saucer”.
A careful review of the abnormal SD OCTs in this patient 
and others in the study also demonstrated that SD OCT 
testing could show a spectrum of findings that correspond 
to progression between different stages of HCQ toxicity. 
Figure 4A shows patient 24, who presented with moderate 
vision loss and clinically significant bull’s eye maculopathy 
that was even more apparent on FAF; a small layer of 
intact foveal IS/OS photoreceptors allowed her to maintain 
20/40 visual acuity. Figure 4B shows patient 18, who had 
advanced foveal atrophy, dense paracentral scotomas, and 
complete outer retinal disruption on SD OCT; her vision was 
hand motions. These progressive SD OCTs also reveal an 
increasing visualization of the choriocapillaris due to retinal 
atrophy with progressively increasing levels of toxicity.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Figure 4 Spectral domain optical coherence tomography (SD OCT) images, red-free photos, and fundus autofluorescence (FAF) demonstrate a spectrum of findings 
seen with different stages of hydroxychloroquine retinopathy. note the increased signal of choroidal vessels on sD OCT as the retina becomes increasingly atrophic with 
progressive toxicity starting from early toxicity in patient 10 seen in Figure 3. A) Moderate toxicity. Patient 24: vision loss, clinical bull’s eye maculopathy even more apparent 
on FAF, Humphrey visual field (HVF) 10-2 paracentral scotomas, and significant perifoveal outer retinal dropout but preservation of central photoreceptor inner segment/
outer segment junction (between the arrows) seen on SD OCT allowing 20/40 vision. B) Late toxicity. Patient 18: severe vision loss to hand motion, pronounced clinical and 
FAF bull’s eye maculopathy, dense HVF 10-2 paracentral scotomas, and complete disruption of outer retinal structures on SD OCT.
In the patient with the normal funduscopic exam, changes 
on SD OCT imaging allowed us to detect HCQ retinopathy 
that was suggested by HVF but could have otherwise gone 
undetected on clinical examination alone. A lack of SD OCT 
findings was also helpful in ruling out true HCQ toxicity 
when ophthalmoscopic fundus exam or other imaging 
modalities including HVF were inconclusive. As toxicity 
can present as a spectrum of disease, any macular changes 
or abnormalities seen on HVF in a patient on HCQ therapy 
needs to be further evaluated for possible retinopathy. Upon 
further review, of the nine patients who had abnormal 
funduscopic exams even potentially attributable to HCQ 
retinopathy, only the four with both SD OCT and HVF 
changes were deemed to have true HCQ retinopathy. Of the 
15 other individuals with normal funduscopic findings, eight 
had abnormalities on HVF perimetry; aside from patient 10 
discussed previously, when these “abnormal” HVF cases 
where analyzed together with their accompanying normal SD 
OCT findings, none of the patients were judged clinically to 
have signs of HCQ toxicity.
For patients being treated with HCQ, SD OCT may play 
an important potential role in screening, as there remains a 
lack of a true “gold” standard in detecting HCQ retinopathy 
before vision loss has occurred. Clinical funduscopic find-
ings can be very subtle and tend to be a late finding, and 
Amsler grid findings can be very subjective. HVF perimetry 
has a steep learning curve and can be very difficult for some 
patients, leading to nonspecific and inconclusive results. 
In addition, most retina specialists do not have HVF in their 
offices and HVF may require separate scheduling to allow 
for an undilated test. Other modalities such as multifocal 
ERGs (mERG) have been shown to potentially identify HCQ 
toxicity changes at an earlier stage; however, mERGs are 
expensive, require special training for administration and 
interpretation, and are not readily available.
This study demonstrates that unique SD OCT findings 
in the retina can identify early HCQ retinopathy using 
commercially available SD OCT systems and may play a com-
plementary role in screening patients in addition to a compre-
hensive eye exam and HVF testing. SD OCT imaging allows 
for anatomical changes to be identified, eliminating potential 
errors from poor patient participation and diminishing the 
need for further testing when nonspecific changes are identi-
fied either on clinical exam or HVF testing. Characteristic 
perifoveal photoreceptor IS/OS junction loss and thinning 
of outer retinal structures in areas of early HCQ toxicity can 
be identified on SD OCT, leading to the “flying saucer” sign 
in the central fovea. A lack of SD OCT changes can also be 
useful in further evaluating cases of questionable fundus or 
visual field changes. Given the increasing availability of SD Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1158
Chen et al
OCT in many retina practices, the ease of image acquisition, 
the lack of subjective findings, and the ability to register and 
compare images from visit to visit, SD OCT may prove to be 
an effective, reliable, and efficient tool to add to the protocol 
for HCQ toxicity screening.
Summary statement
Spectral domain optical coherence tomography may have a 
role in the detection of early hydroxychloroquine retinopathy 
because of its short acquisition time and greater objectivity 
relative to automated visual field testing. Perifoveal photo-
receptor inner segment/outer segment junction disruption 
(the “flying saucer” sign) can be used to detect early toxicity, 
sometimes even before the appearance of clinical fundus 
changes.
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